Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2025 Oct:247:108293.
doi: 10.1016/j.rmed.2025.108293. Epub 2025 Aug 5.

Efficacy and safety of novel fixed dose combination of vilanterol, glycopyrronium, and fluticasone furoate dry powder inhaler: A phase 3, randomized, non-inferiority trial compared with fixed dose combination of indacaterol, glycopyrronium, and mometasone furoate dry powder inhaler in Indian asthma patients

Chintan Patel  1 , Vaishal Sheth  2 , Ravi Koppula  3 , Avadhesh Kumar  4 , Amit S Bhate  5 , Diptikant Sahoo  6 , Manish Kumar Jain  7 , Asish Mondal  8 , Deven Parmar  9 , Kevinkumar Kansagra  9 , Rahul Shrivastava  9 , Hardik Pathak  10
Affiliations
Clinical Trial

Efficacy and safety of novel fixed dose combination of vilanterol, glycopyrronium, and fluticasone furoate dry powder inhaler: A phase 3, randomized, non-inferiority trial compared with fixed dose combination of indacaterol, glycopyrronium, and mometasone furoate dry powder inhaler in Indian asthma patients

Chintan Patel et al. Respir Med. 2025 Oct.

Abstract

Background: For managing persistent asthma, M/s. Zydus Healthcare Limited has developed a novel fixed dose combination (FDC) of vilanterol 25 μg, glycopyrronium 50 μg, and fluticasone furoate 200 μg (VIL-GLY-FF) in dry powder inhaler (DPI) formulation.

Methods: This phase 3, multicenter, parallel group, open-label study randomized (1:1) patients not controlled with medium or high-dose inhaled corticosteroid in either the test (VIL-GLY-FF DPI) or reference (approved FDC DPI of indacaterol 150 μg, GLY 50 μg, and mometasone furoate 160 μg [IND-GLY-MF]) group. FDCs were administered by inhaling one capsule via Respihaler device once-daily for 12 weeks. The primary endpoint was the change in trough forced expiratory volume in 1 s (FEV1) at week 12 from baseline. Secondary outcomes included the comparison of trough forced vital capacity (FVC), post-bronchodilator FEV1 and FVC, and asthma control test score between the two groups.

Findings: All 256 enrolled patients completed the study. The least square mean (standard error) change in trough FEV1 at week 12 from baseline was 392.77 (31.33) ml and 364.34 (31.33) ml for the test and reference groups (p = 0.522), respectively. The lower limit of 95 % confidence interval for the difference between two groups for the mean change in trough FEV1 at week 12 from baseline was -58.83 ml, well-above the predefined non-inferiority margin (-150 ml). Other secondary endpoints and safety were comparable between the two groups.

Interpretation: VIL-GLY-FF DPI was found non-inferior to IND-GLY-MF DPI in improving trough FEV1 response. The test FDC was well-tolerated in Indian patients with persistent asthma.

Clinical trial registration number: CTRI/2024/02/063046 (Clinical Trial Registry - India).

Keywords: Asthma; Fluticasone furoate; Glycopyrronium; Non-inferiority; Phase 3; Randomized; Vilanterol; dry powder inhaler.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:Kevinkumar Kansagra, Deven Parmar, Rahul Shrivastava, and Hardik Pathak are employees of Zydus Lifesciences Ltd., Ahmedabad, India. All other authors have no conflict of interests to declare. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

MeSH terms